NewLink Genetics Corporation Company Profile (NASDAQ:NLNK)

NewLink Genetics Corporation trades on the NASDAQ under the ticker symbol "NLNK."

NewLink Genetics Corporation (NASDAQ:NLNK) released its quarterly earnings data on Friday, July, 28th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.21. The firm earned $10.37 million during the quarter, compared to analysts' expectations of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. View NewLink Genetics Corporation's Earnings History.

NewLink Genetics Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for NewLink Genetics Corporation.

6 brokers have issued 12-month price targets for NewLink Genetics Corporation's shares. Their forecasts range from $22.00 to $30.00. On average, they expect NewLink Genetics Corporation's stock price to reach $25.83 in the next twelve months. View Analyst Ratings for NewLink Genetics Corporation.

Here are some recent quotes from research analysts about NewLink Genetics Corporation stock:

• 1. Cantor Fitzgerald analysts commented, "Incremental Data Points in the Right Direction. Updated data from the Phase I/II trial in advanced melanoma (excluding ocular melanoma), showed improving complete responses (CRs) to 20% vs. 12% reported at six months. The overall response rate (ORR) and disease control rate (DCR) were stable at 61% and 80%, respectively, vs. 59% and 80% at six months." (9/8/2017)
• 2. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (7/29/2017)
• 3. Stifel Nicolaus analysts commented, "NLNK shares are looking increasingly actionable ahead of what we believe could prove to be a transformational next 1-6 months ' highlighted by two indoximod-related presentations at the upcoming AACR meeting and a critical mid-FY17 data disclosure from partner Roche. We believe incremental data from the P2 trial evaluating the combination of indoximod/pembrolizumab will provide an apples/apples comparison to Incyte/Merck's epacadostat/pembrolizumab P2 melanoma data ' potentially dispelling the prevailing 'I DON'T' inhibitor thesis and providing a future runway for value attribution (now made even easier with the recent filing of additional formulation-related IP). We believe P1b data from the Roche development program evaluating the combination of atezolizumab/GDC-0919 may represent the first mechanistic/translational evidence supporting the contribution of IDO inhibition to an immunotherapy-based regimen ' significantly improving visibility into a meaningful stream of future non-dilutive revenue. Target increased to $26 (previously $22)." (3/1/2017)
• 4. Jefferies Group LLC analysts commented, "NLNK plans to present more data on indoximod throughout 2017. At AACR in April there will be updated data on the pembro combo in melanoma with some baseline characteristics as well as preclinical data on the prodrug formulation of indoximod. Titles of these abstracts will be released tomorrow at 4:30pm. Additional data will be seen from the panc cancer trial combo with gem/ Abraxane in 2H17. We continue to await data from the GDC-0919 program." (3/1/2017)

NewLink Genetics Corporation saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 7,917,401 shares, an increase of 42.7% from the August 31st total of 5,547,335 shares. Based on an average trading volume of 9,112,435 shares, the days-to-cover ratio is currently 0.9 days. Approximately 36.5% of the company's shares are short sold.

Some companies that are related to NewLink Genetics Corporation include Mesoblast Limited (MESO), Celyad SA (CYAD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), PDL BioPharma (PDLI), Agenus (AGEN), Kala Pharmaceuticals (KALA), Adamas Pharmaceuticals (ADMS), Cara Therapeutics (CARA), Celldex Therapeutics (CLDX), Arbutus Biopharma Corporation (ABUS), Idera Pharmaceuticals (IDRA), Codexis (CDXS), Protagonist Therapeutics (PTGX), Concert Pharmaceuticals (CNCE), Corvus Pharmaceuticals (CRVS), Puretech Health PLC (PRTC) and Novavax (NVAX).

NewLink Genetics Corporation's management team includes the folowing people:

• Charles J. Link Jr. M.D., Chairman of the Board, Chief Executive Officer, Chief Scientific Officer
• John Bell Henneman III, Chief Financial Officer, Secretary
• Brian Wiley, Chief Commercial Officer
• Thomas A. Raffin M.D., Lead Independent Director
• Paolo Pucci, Director
• Paul R. Edick, Independent Director
• Ernest J. Talarico III, Independent Director
• Lota S. Zoth CPA, Independent Director

NewLink Genetics Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional investors include STINE SEED FARM, INC. (21.20%) and INTEGRATED CORE STRATEGIES (US) LLC (5.80%). Company insiders that own NewLink Genetics Corporation stock include Brian Wiley, Carl W Langren, Charles J Jr Link, John B Henneman III and Stine Seed Farm, Inc. View Institutional Ownership Trends for NewLink Genetics Corporation.

Shares of NewLink Genetics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NewLink Genetics Corporation stock can currently be purchased for approximately $10.18.